Inhibition of gastric acid is the key to satisfactory relief of symptoms and restoration of the quality of life in patients with epigastric pain related to non-ulcer dyspepsia during therapy with esomeprazole

Trial Profile

Inhibition of gastric acid is the key to satisfactory relief of symptoms and restoration of the quality of life in patients with epigastric pain related to non-ulcer dyspepsia during therapy with esomeprazole

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2016

At a glance

  • Drugs Esomeprazole (Primary)
  • Indications Non-ulcer dyspepsia
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 May 2015 Status changed from withdrawn prior to enrolment to completed as per ClinicalTrials.gov record.
    • 16 Feb 2011 Status changed from completed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 01 Jul 2008 The expected completion date for this trial is now 1 Jan 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top